ClinicalTrials.gg
DrugBiological

Nidanilimab clinical trials

Also written Nadunolimab and CAN04.

studies test it
7
open now
3
in phase 3
0
first study started
2017

How each study uses nidanilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the nidanilimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

CAN04
4

Other names

Nadunolimab
5

Studies by the year they started

7 studies that test it; most in 2025 (2)

Studies that test nidanilimab, by start year
YearStudies
20171
20201
20211
20221
20252
20261

By phase

A phase 1/2 study counts in both.

Phase 1
6
Phase 2
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 4 · Other 3

Cantargia AB (4) · M.D. Anderson Cancer Center (1) · Robert Samstein (1) · Dan Feng (1)

Studies

Open first, then newest update. How each study uses nidanilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 7

Given beside what is tested · 1 — nidanilimab is usual care or a partner of the new treatment

Codes

What other systems call nidanilimab · ClinicalTrials.gg INT017378

  • UNII (FDA) ND296JF21INIDANILIMABOne source FDA
  • NCI Thesaurus C153375NidanilimabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.